

## REPORT ON THE REVIEW OF THE SIMPLIFIED INTERIM FINANCIAL STATEMENTS

To the shareholders of  
ANTIBIOTICE S.A.

### **Introduction**

We have reviewed the accompanying interim condensed financial statements of ANTIBIOTICE S.A. (the "Company") for the period from January 1, 2025 to June 30, 2025. The interim condensed financial statements include: (i) the interim condensed statement of the financial position as of June 30, 2025, (ii) the interim condensed statement of profit or loss and other comprehensive income, the interim condensed statement of changes in equity and the interim condensed statement of cash flows, each for the period from January 1, 2025 to June 30, 2025, and comparative information for the period from January 1, 2024 to June 30, 2024, and (iii) other explanatory notes.

The management is responsible for the preparation and presentation of these simplified interim financial statements prepared in accordance with the Order of the Minister of Public Finance no. 2844/2016 as amended.

Our responsibility is to express a conclusion on these simplified interim financial statements, based on our review.

### **Scope of the review**

We conducted our review in accordance with the International Standard on Review Engagements 2410, "Review of Interim Financial Statements Performed by an Independent Auditor of the Entity." A review of interim financial statements consists of making inquiries, particularly of those responsible for the financial statements, and performing analytical and other review procedures.

The scope of a review is significantly less than that of an audit conducted in accordance with International Standards on Auditing and therefore we cannot obtain assurance that we will become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### **Conclusion**

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed interim financial statements do not present fairly, in all material respects, the financial position of the entity as of June 30, 2025 and its financial performance and cash flows for the six-month period then ended in accordance with the Order of the Minister of Public Finance no. 2844/2016, as amended.

### **Relevant aspects related thereto**

We draw attention to the fact that we have not audited or reviewed the interim simplified statements of profit or loss and the comprehensive income for the three-month periods ended on June 30, 2025 and June 30, 2024 and we do not accordingly express an opinion or conclusion thereon.

Deloitte relates to one or more of the Deloitte Touche Tohmatsu Limited ("DTTL"), its global network of member firms and their affiliated entities (collectively, the "Deloitte organization"). DTTL (also referred to as "Deloitte Global") and each of its member firms and affiliated entities are independent and legally separate entities that cannot bind or commit each other with respect to third parties. DTTL and each DTTL member firm and associated entity are solely liable for their own acts and omissions and not for those of other entities. DTTL does not provide services to clients. To learn more, please visit [www.deloitte.com/ro/despre](http://www.deloitte.com/ro/despre).

This report is addressed solely to the shareholders of the Company as a whole. Our review was conducted in order to report to the shareholders of the Company those matters that we are required to report in a review report, and for no other purpose. To the extent permitted by law, we do not accept or assume responsibility other than to the Company and its shareholders as a whole for our review, for this report or for the conclusion we reached.

On behalf of:  
Deloitte Audit S.R.L.

Alina Ioana Mirea

*Illegible signature and stamp*

Bucharest, Romania  
August 13, 2025